Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not malesSTOLL, S; HAFNER, U; KRÄNZLIN, B et al.Neurobiology of aging. 1997, Vol 18, Num 2, pp 205-211, issn 0197-4580Article

Pharmacokinetic evaluation of a selegiline pulsatile oral delivery systemROHATAGI, S; BARRETT, J. S; DEWITT, K. E et al.Biopharmaceutics & drug disposition. 1997, Vol 18, Num 8, pp 665-680, issn 0142-2782Article

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonismKIROLLOS, C; CHARLETT, A; DOBBS, R. J et al.European journal of clinical pharmacology. 1996, Vol 50, Num 1-2, pp 7-18, issn 0031-6970Article

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's diseaseJENNER, Peter.Neurology. 2004, Vol 63, Num 7, pp S13-S22, issn 0028-3878, SUP2Article

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibitionCLARKE, A; JOHNSON, E. S; MALLARD, N et al.Journal of neural transmission. 2003, Vol 110, Num 11, pp 1257-1271, issn 0300-9564, 15 p.Article

Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline : Interventions, Part IIIYOUDIM, Moussa B. H; WEINSTOCK, Marta.Mechanisms of ageing and development. 2002, Vol 123, Num 8, pp 1081-1086, issn 0047-6374Conference Paper

Effects of selegiline pretreatment on response to experimental cocaine administrationNEWTON, T. F; KALECHSTEIN, A; BECKSON, M et al.Psychiatry research. 1999, Vol 87, Num 2-3, pp 101-106, issn 0165-1781Article

Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administrationROHATAGI, S; BARRETT, J. S; DEWITT, K. E et al.Biopharmaceutics & drug disposition. 1997, Vol 18, Num 7, pp 567-584, issn 0142-2782Article

Selegiline transdermal system for the treatment of major depressive disorder : An 8-week, double-blind, placebo-controlled, flexible-dose titration trialFEIGER, Alan D; RICKELS, Karl; RYNN, Moira A et al.The Journal of clinical psychiatry. 2006, Vol 67, Num 9, pp 1354-1361, issn 0160-6689, 8 p.Article

Chiral separation of deprenyl-N-oxide isomers by capillary electrophoresis using various cyclodextrin derivativesTABI, Tamas; HALASZ, Attila Sandor; PALFI, Melinda et al.Journal of chromatographic science. 2004, Vol 42, Num 1, pp 21-26, issn 0021-9665, 6 p.Article

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibitionCLARKE, A; BREWER, F; JOHNSON, E. S et al.Journal of neural transmission. 2003, Vol 110, Num 11, pp 1241-1255, issn 0300-9564, 15 p.Article

Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitroMOHANKUMAR, P. S; MOHANKUMAR, Sheba M. J; QUADRI, S. K et al.Brain research bulletin. 2001, Vol 54, Num 6, pp 675-680, issn 0361-9230Article

Tyrosine hydroxylase deficiency with severe clinical course : Clinical and biochemical investigations and optimization of therapyDIONISI-VICI, C; HOFFMANN, G. F; LEUZZI, V et al.The Journal of pediatrics. 2000, Vol 136, Num 4, pp 560-562, issn 0022-3476Article

Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbilsERDÖ, F; BARANYI, A; TAKACS, J et al.Neuroreport (Oxford). 2000, Vol 11, Num 11, pp 2597-2600, issn 0959-4965Article

Biotransformation of deprenyl enantiomersSZÖKO, E; KALASZ, H; MAGYAR, K et al.European journal of drug metabolism and pharmacokinetics. 1999, Vol 24, Num 4, pp 315-319, issn 0378-7966Article

Deprenyl, excess mortality, and epidemiological trapsRIGGS, J. E.Clinical neuropharmacology. 1997, Vol 20, Num 3, pp 276-278, issn 0362-5664Article

Influence of selegiline and lipoic acid on the life expectancy of immunosuppressed miceFREISLEBEN, H.-J; NEEB, A; LEHR, F et al.Arzneimittel-Forschung. 1997, Vol 47, Num 6, pp 776-780, issn 0004-4172Article

Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegilineKORN, A; WAGNER, B; MORITZ, E et al.European journal of clinical pharmacology. 1996, Vol 49, Num 4, pp 273-278, issn 0031-6970Article

The role of selegiline in the treatment of negative symptoms associated with schizophreniaFOHEY, Krista D; HIEBER, Robin; NELSON, Leigh Anne et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 5, pp 851-856, issn 1060-0280, 6 p.Article

Marked effect of liver and kidney function on the pharmacokinetics of selegilineANTTILA, Markku; SOTANIEMI, Eero A; PELKONEN, Olavi et al.Clinical pharmacology and therapeutics. 2005, Vol 77, Num 1, pp 54-62, issn 0009-9236, 9 p.Article

Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatmentTHYAGARAJAN, S; STEVENS, S. Y; FELTEN, D. L et al.Brain research bulletin. 1999, Vol 48, Num 5, pp 513-520, issn 0361-9230Article

Isatin : A link between natriuretic peptides and monoamines ?MEDVEDEV, A. E; CLOW, A; SANDLER, M et al.Biochemical pharmacology. 1996, Vol 52, Num 3, pp 385-391, issn 0006-2952Article

Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administrationLAJTHA, A; SERSHEN, H; COOPER, T et al.Neurochemical research. 1996, Vol 21, Num 10, pp 1155-1160, issn 0364-3190Article

Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridiniumKOUTSILERI, E; CHEN, T.-S; RAUSCH, W.-D et al.European journal of pharmacology. 1996, Vol 306, Num 1-3, pp 181-186, issn 0014-2999Article

Selegiline transdermal system (STS): Assessments of dermal safety in humanPAUPORTE, Michele; AZZARO, Albert J; MOONSAMMY, George et al.Journal of toxicology. Cutaneous and ocular toxicology. 2004, Vol 23, Num 3, pp 179-187, issn 0731-3829, 9 p.Article